Umangi Patel1,2, Carol L Karp1, Sander R Dubovy1,2. 1. Anne Bates Leach Eye Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. 2. Florida Lions Ocular Pathology Laboratory, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Abstract
PURPOSE OF REVIEW: To review and update the latest findings in diagnosis and management of ocular surface squamous neoplasia (OSSN). RECENT FINDINGS: OSSN is the most common anterior segment neoplastic disease process. Several ocular surface imaging techniques have been developed for the early diagnosis and management of clinical and subclinical ocular surface squamous neoplasia, including high-resolution optical coherence tomography (HR-OCT), in vivo confocal microscopy, and ultrasound biomicroscopy. Treatment modalities include both surgical and medical management, with a recent trend towards primary and adjunctive pharmacotherapy. SUMMARY: There is increasing use of HR-OCT for the diagnosis and monitoring of clinical and subclinical OSSN lesions. Topical pharmacotherapy agents, including interferon α-2b, 5-fluorouracil, and mitomycin C, have demonstrable efficacy in the treatment of OSSN and their use may be dictated based upon tumor factors, patient factors, cost, and side effect profile. Both surgical excision and adjunctive topical medications have excellent success, with the favored treatment method trending towards topical pharmacotherapy as primary therapy.
PURPOSE OF REVIEW: To review and update the latest findings in diagnosis and management of ocular surface squamous neoplasia (OSSN). RECENT FINDINGS: OSSN is the most common anterior segment neoplastic disease process. Several ocular surface imaging techniques have been developed for the early diagnosis and management of clinical and subclinical ocular surface squamous neoplasia, including high-resolution optical coherence tomography (HR-OCT), in vivo confocal microscopy, and ultrasound biomicroscopy. Treatment modalities include both surgical and medical management, with a recent trend towards primary and adjunctive pharmacotherapy. SUMMARY: There is increasing use of HR-OCT for the diagnosis and monitoring of clinical and subclinical OSSN lesions. Topical pharmacotherapy agents, including interferon α-2b, 5-fluorouracil, and mitomycin C, have demonstrable efficacy in the treatment of OSSN and their use may be dictated based upon tumor factors, patient factors, cost, and side effect profile. Both surgical excision and adjunctive topical medications have excellent success, with the favored treatment method trending towards topical pharmacotherapy as primary therapy.
Authors: Juan C Murillo; Anat Galor; Michael C Wu; Natasha K Kye; James Wong; Ibrahim O Ahmed; Madhura Joag; Nabeel Shalabi; William Lahners; Sander Dubovy; Carol L Karp Journal: Ocul Oncol Pathol Date: 2016-10-21
Authors: J Frucht-Pery; J Sugar; J Baum; J E Sutphin; J Pe'er; H Savir; E J Holland; D M Meisler; J A Foster; R Folberg; Y Rozenman Journal: Ophthalmology Date: 1997-12 Impact factor: 12.079